What is Beam Therapeutics's R&D?

Beam Therapeutics (BEAM) reported R&D of $104.52M in Q1 2026.

How has Beam Therapeutics's R&D changed year-over-year?

Beam Therapeutics's R&D increased by 5.8% year-over-year, from $98.82M to $104.52M.

What is the long-term trend for Beam Therapeutics's R&D?

Over 4 years (2021 to 2025), Beam Therapeutics's R&D has grown at a 1.4% compound annual growth rate (CAGR), from $387.09M to $409.62M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Beam Therapeutics BEAM R&D

R&D at other companies

Arrowhead ResearchARWR

$173.25M+30.2%

CRISPR TherapeuticsCRSP

$68.57M-5.4%

Cogent Biosciences, Inc.COGT

$75.37M+19.6%

PTC TherapeuticsPTCT

$100.87M-7.4%

BridgeBio PharmaBBIO

$126.64M+13.6%

Protagonist TherapeuticsPTGX

$46.74M+30.2%

Segments

By segment

See full

Employee Related Expenses$32.87M+12.4%

External Research And Development Expenses$30.08M-12.6%

Other financials

Income statement

See full

Revenue$31.7M+325%

Operating income-$107.2M+10.1%

Net income-$94.3M+12.9%

EPS (diluted)-$0.91+26.0%

Balance sheet

See full

Cash & equivalents$288.3M-45.4%

Total debt$250.8M+58.6%

Total equity$1.2B+3.1%

Total assets$1.5B+0.9%

Cash flow

See full

Operating cash flow-$128.5M-23.7%

CapEx$2.2M-27.2%

Free cash flow-$130.7M-22.2%

Valuation

See full

Market cap$3.51B+24.5%

Enterprise value$3.47B+51.2%

P/S21.4×-23.0×

Profitability

See full

Operating margin-226.6%-90.5pp

Net margin-742.7%—

FCF margin-234%-86.6pp

Returns & leverage

See full

Return on equity-47.1%—

Debt / equity0.2×+0.1×

Current ratio17×+8.2×

Where this comes from

Reported directly by Beam Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Beam Therapeutics's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Beam Therapeutics's R&D?: Beam Therapeutics (BEAM) reported R&D of $104.52M in Q1 2026.
How has Beam Therapeutics's R&D changed year-over-year?: Beam Therapeutics's R&D increased by 5.8% year-over-year, from $98.82M to $104.52M.
What is the long-term trend for Beam Therapeutics's R&D?: Over 4 years (2021 to 2025), Beam Therapeutics's R&D has grown at a 1.4% compound annual growth rate (CAGR), from $387.09M to $409.62M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.